Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Drug Profile

Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Alternative Names: Cancer therapeutics - Lixte; LB-1.2; LB-102; LB-2.1; LB-200 series - Lixte; LB-201; LB-205; LB-300 series - Lixte; LB-400 series - Lixte; Neurological therapeutics - Lixte

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer Lixte Biotechnology Holdings; National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA)
  • Class Antineoplastics; Cycloheptanes; Neuroprotectants; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Phosphoprotein phosphatase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Cancer; Gaucher's disease; Mycoses; Neurological disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gaucher's-disease in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top